NCT06299930

Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy Based on Tumor Subtypes in Patients With Early-stage Breast Cancer: A Multi-institutional Retrospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10,328 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 100 Years
• Healthy volunteers: —

Summary

Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
PROCEDURE	Neoadjuvant chemotherapy	Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
PROCEDURE	Adjuvant chemotherapy	Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy

Timeline

• Start date: 2022-04-22
• Primary completion: 2023-08-16
• Completion: 2023-09-12
• First posted: 2024-03-08
• Last updated: 2024-03-08

Locations

1 site across 1 country: South Korea